Login / Signup

Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.

Samantha PhouCaitlin CostelloPatricia M KopkoElizabeth S Allen
Published in: Transfusion (2021)
The incidence of alloimmunization in patients receiving daratumumab is low. Whether this is due to the effect of daratumumab, underlying pathophysiology, or other factors, is unknown. Because these patients require a large number of RBC transfusions overall and have little observed alloimmunization, phenotype matching (beyond RhD) may be unnecessary. Since the use of dithiothreitol cannot rule out the presence of anti-K, we recommend transfusion of ABO-compatible units, prophylactically matched for the D and K antigens only.
Keyphrases